The FTC lawsuit accuses the PBMs of unfairly limiting access to insulin drugs with lower list prices and steering diabetes ...

The U.S. Federal Trade Commission's lawsuit against pharmacy benefit managers over insulin pricing practices will likely move ...

Created in 1914, the FTC is tasked with stopping unfair trade practices — particularly those by big corporations that use ...

An FTC in-house case against major US drug middlemen that was thrown in limbo by President Donald Trump’s firing of two ...

Denouncing the $557 billion industry as “horrible middlemen,” responsible for—and “rich as hell” from— America’s incomparably high prescription drug prices, Trump vowed to get rid of ...

Although there are additional reasons for drug shortages, at their root are these healthcare supply chain middlemen who hold such immense power over large contracts and control production.

A House panel Wednesday approved a bill aimed at preventing pharmacy benefit managers (PBMs) from holding a permit to operate ...

PBMs act as middlemen between drug companies and consumers. They negotiate volume discounts and fees with drug manufacturers on behalf of employers and health plans, create lists of medications ...

She said in a statement on Friday that she would remain recused. PBMs negotiate volume discounts and fees with drug manufacturers on behalf of employers and health plans, create lists of ...